18 and older, male only, with Castration-Resistant Prostate Carcinoma or Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Lowest On-treatment Prostate Specific Antigen (PSA)Primary· At least 12 weeks of olaparib treatment
The proportion of patients achieving at least a 50% decline in PSA from baseline will be presented.
Group
Value
95% CI
Treatment (Olaparib)
0
Overall Response Rate (ORR)Secondary· Up to 12.3 weeks
Will be defined as the proportion of participants demonstrating at least a 30% decrease in total tumor size from baseline per Response Evaluation Criteria in Solid Tumors 1.1 criteria at any time point. The percent of patients with ORR and range of values will be provided.
Group
Value
95% CI
Treatment (Olaparib)
0
Radiographic Progression Free Survival (PFS)Secondary· Up to 12.3 weeks
Radiographic progression will be determined as using RECIST v1.1 and/or PCWG3 criteria. Median PFS will be estimated using the Kaplan-Meier method.
Group
Value
95% CI
Treatment (Olaparib)
12.3
11 – 12.3
Prostate Specific Antigen (PSA) Progression Free Survival (PFS)Secondary· Up to 16.6 weeks
PSA progression will be time to for the PSA to increase by at least 2 ng/ml and ≥20% above baseline. PSA PFS will be the time until PSA progression and will be analyzed using kaplan meier method, with the median PSA PFS reported
Group
Value
95% CI
Treatment (Olaparib)
12
12 – 16.6
Overall SurvivalSecondary· Up to 12.3 weeks
Number of patients who died on study. Note: Plan was to assess time from enrollment to death; however, no deaths have been observed.
Group
Value
95% CI
Treatment (Olaparib)
0
Adverse events — posted to ClinicalTrials.gov
Time frame: Within 30 days of end of treatment, up to 16.6 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br
· Phase 2
· not yet recruiting
NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
· Phase 2
· not yet recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
· Phase 1
· recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che
· Phase 2
· not yet recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo
· Phase 3
· recruiting
Other recruiting trials for Castration-Resistant Prostate Carcinoma
Currently open trials in the same condition.
NCT06942104 — Imaging of Solid Tumors Using 18F-TRX
· Phase 1
· recruiting
NCT06632977 — Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
· Phase 2
· recruiting
NCT06305598 — Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration
· Phase 1
· recruiting
NCT06236139 — Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate
· Phase 1, PHASE2
· recruiting
NCT06145633 — Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
· Phase 2
· recruiting
Other University of Washington trials
Trials by the same sponsor.
NCT07430852 — Inherited and Environmental Risks Acting on Body Weight
· NA
· not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc
· Phase 2
· not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn
· NA
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 1 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04951492.